Biosimilars Market Size, Trends, Analysis, and Outlook By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic & Autoimmune Disorders, Others), by Country, Segment, and Companies, 2024-2032
The global Biosimilars market size is poised to register 12.5% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Biosimilars market across By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Rheumatoid Arthritis, Chronic & Autoimmune Disorders, Others)
The biosimilars market is characterized by the increasing competition in the biopharmaceutical industry, regulatory pathways for biosimilar approval, and the need for affordable and accessible biologic therapies. By 2030, the market is poised to witness significant growth, driven by the launch of biosimilar products, expanding therapeutic indications, and patent expirations of reference biologics. Further, increasing acceptance by healthcare providers, payers, and patients is expected to drive market expansion, enabling biosimilar manufacturers to capture market share, reduce healthcare costs, and improve patient access to biologic treatments.
Biosimilars Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilars market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilars survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilars industry.
Key market trends defining the global Biosimilars demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Biosimilars Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Biosimilars industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilars companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Biosimilars industry
Leading Biosimilars companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilars companies.
Biosimilars Market Study- Strategic Analysis Review
The Biosimilars market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
The Biosimilars industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Biosimilars Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Biosimilars Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Biosimilars market segments. Similarly, Strong market demand is encouraging Canadian Biosimilars companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Biosimilars market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Biosimilars Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Biosimilars industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Biosimilars market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Biosimilars Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilars in Asia Pacific. In particular, China, India, and South East Asian Biosimilars markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Biosimilars Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Biosimilars Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilars market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilars.
Biosimilars Market Company Profiles
The global Biosimilars market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Amega Biotech S.A.S., Amgen Inc, Amneal Pharmaceuticals Inc, Apotex Inc, BIOCAD, Biocon Ltd, Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd, Coherus BioSciences Inc, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, Fujifilm Kyowa Kirin Biologics Co. Ltd, Intas Pharmaceuticals Ltd, Kashiv Biosciences LLC, mAbxience S.L., Novartis AG, Pfizer Inc, Probiomed S.A. de C.V., Reliance Life Sciences Pvt. Ltd, Samsung Bioepis Co. Ltd, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd, USV Private Ltd.
Recent Biosimilars Market Developments
The global Biosimilars market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Biosimilars Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
By Product
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Rheumatoid Arthritis
Chronic & Autoimmune Disorders
Others
Geographical Segmentation:
Amega Biotech S.A.S.
Amgen Inc
Amneal Pharmaceuticals Inc
Apotex Inc
BIOCAD
Biocon Ltd
Boehringer Ingelheim International GmbH
Celltrion Healthcare Co. Ltd
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius SE & Co. KGaA
Fujifilm Kyowa Kirin Biologics Co. Ltd
Intas Pharmaceuticals Ltd
Kashiv Biosciences LLC
mAbxience S.L.
Novartis AG
Pfizer Inc
Probiomed S.A. de C.V.
Reliance Life Sciences Pvt. Ltd
Samsung Bioepis Co. Ltd
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd
USV Private Ltd
Formats Available: Excel, PDF, and PPT
The biosimilars market is characterized by the increasing competition in the biopharmaceutical industry, regulatory pathways for biosimilar approval, and the need for affordable and accessible biologic therapies. By 2030, the market is poised to witness significant growth, driven by the launch of biosimilar products, expanding therapeutic indications, and patent expirations of reference biologics. Further, increasing acceptance by healthcare providers, payers, and patients is expected to drive market expansion, enabling biosimilar manufacturers to capture market share, reduce healthcare costs, and improve patient access to biologic treatments.
Biosimilars Market Drivers, Trends, Opportunities, and Growth Opportunities
This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Biosimilars market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Biosimilars survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Biosimilars industry.
Key market trends defining the global Biosimilars demand in 2024 and Beyond
The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.
Biosimilars Market Segmentation- Industry Share, Market Size, and Outlook to 2032
The Biosimilars industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Biosimilars companies scaling up production in these sub-segments with a focus on expanding into emerging countries.
Key strategies adopted by companies within the Biosimilars industry
Leading Biosimilars companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Biosimilars companies.
Biosimilars Market Study- Strategic Analysis Review
The Biosimilars market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-
- Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
- Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
- Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
- Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.
The Biosimilars industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.
Biosimilars Country Analysis and Revenue Outlook to 2032
The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.
North America Biosimilars Market Size Outlook- Companies plan for focused investments in a changing environment
The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to $4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Biosimilars market segments. Similarly, Strong market demand is encouraging Canadian Biosimilars companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Biosimilars market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.
Europe Biosimilars Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities
The German industry remains the major market for companies in the European Biosimilars industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Biosimilars market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.
Asia Pacific Biosimilars Market Size Outlook- an attractive hub for opportunities for both local and global companies
The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Biosimilars in Asia Pacific. In particular, China, India, and South East Asian Biosimilars markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.
Latin America Biosimilars Market Size Outlook- Continued urbanization and rising income levels
Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.
Middle East and Africa Biosimilars Market Size Outlook- continues its upward trajectory across segments
Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Biosimilars market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Biosimilars.
Biosimilars Market Company Profiles
The global Biosimilars market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Amega Biotech S.A.S., Amgen Inc, Amneal Pharmaceuticals Inc, Apotex Inc, BIOCAD, Biocon Ltd, Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd, Coherus BioSciences Inc, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, Fujifilm Kyowa Kirin Biologics Co. Ltd, Intas Pharmaceuticals Ltd, Kashiv Biosciences LLC, mAbxience S.L., Novartis AG, Pfizer Inc, Probiomed S.A. de C.V., Reliance Life Sciences Pvt. Ltd, Samsung Bioepis Co. Ltd, STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd, USV Private Ltd.
Recent Biosimilars Market Developments
The global Biosimilars market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.
Biosimilars Market Report Scope
Parameters: Revenue, Volume Price
Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)
Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)
Qualitative Analysis
- Pricing Analysis
- Value Chain Analysis
- SWOT Profile
- Market Dynamics- Trends, Drivers, Challenges
- Porter’s Five Forces Analysis
- Macroeconomic Impact Analysis
- Case Scenarios- Low, Base, High
By Product
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Rheumatoid Arthritis
Chronic & Autoimmune Disorders
Others
Geographical Segmentation:
- North America (3 markets)
- Europe (6 markets)
- Asia Pacific (6 markets)
- Latin America (3 markets)
- Middle East Africa (5 markets)
Amega Biotech S.A.S.
Amgen Inc
Amneal Pharmaceuticals Inc
Apotex Inc
BIOCAD
Biocon Ltd
Boehringer Ingelheim International GmbH
Celltrion Healthcare Co. Ltd
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius SE & Co. KGaA
Fujifilm Kyowa Kirin Biologics Co. Ltd
Intas Pharmaceuticals Ltd
Kashiv Biosciences LLC
mAbxience S.L.
Novartis AG
Pfizer Inc
Probiomed S.A. de C.V.
Reliance Life Sciences Pvt. Ltd
Samsung Bioepis Co. Ltd
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd
USV Private Ltd
Formats Available: Excel, PDF, and PPT
1. EXECUTIVE SUMMARY
1.1 Biosimilars Market Overview and Key Findings, 2024
1.2 Biosimilars Market Size and Growth Outlook, 2021- 2030
1.3 Biosimilars Market Growth Opportunities to 2030
1.4 Key Biosimilars Market Trends and Challenges
1.4.1 Biosimilars Market Drivers and Trends
1.4.2 Biosimilars Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Biosimilars Companies
2. BIOSIMILARS MARKET SIZE OUTLOOK TO 2030
2.1 Biosimilars Market Size Outlook, USD Million, 2021- 2030
2.2 Biosimilars Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. BIOSIMILARS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. BIOSIMILARS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Rheumatoid Arthritis
Chronic & Autoimmune Disorders
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Biosimilars Market, 2025
5.2 Asia Pacific Biosimilars Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Biosimilars Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Biosimilars Market, 2025
5.5 Europe Biosimilars Market Size Outlook by Type, 2021- 2030
5.6 Europe Biosimilars Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Biosimilars Market, 2025
5.8 North America Biosimilars Market Size Outlook by Type, 2021- 2030
5.9 North America Biosimilars Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Biosimilars Market, 2025
5.11 South America Pacific Biosimilars Market Size Outlook by Type, 2021- 2030
5.12 South America Biosimilars Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Biosimilars Market, 2025
5.14 Middle East Africa Biosimilars Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Biosimilars Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Biosimilars Market Size Outlook and Revenue Growth Forecasts
6.2 US Biosimilars Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Biosimilars Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Biosimilars Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Biosimilars Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Biosimilars Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Biosimilars Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Biosimilars Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Biosimilars Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Biosimilars Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Biosimilars Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Biosimilars Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Biosimilars Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Biosimilars Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Biosimilars Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Biosimilars Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Biosimilars Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Biosimilars Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Biosimilars Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Biosimilars Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Biosimilars Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Biosimilars Industry Drivers and Opportunities
7. BIOSIMILARS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. BIOSIMILARS COMPANY PROFILES
8.1 Profiles of Leading Biosimilars Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Amega Biotech S.A.S.
Amgen Inc
Amneal Pharmaceuticals Inc
Apotex Inc
BIOCAD
Biocon Ltd
Boehringer Ingelheim International GmbH
Celltrion Healthcare Co. Ltd
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius SE & Co. KGaA
Fujifilm Kyowa Kirin Biologics Co. Ltd
Intas Pharmaceuticals Ltd
Kashiv Biosciences LLC
mAbxience S.L.
Novartis AG
Pfizer Inc
Probiomed S.A. de C.V.
Reliance Life Sciences Pvt. Ltd
Samsung Bioepis Co. Ltd
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd
USV Private Ltd.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
1.1 Biosimilars Market Overview and Key Findings, 2024
1.2 Biosimilars Market Size and Growth Outlook, 2021- 2030
1.3 Biosimilars Market Growth Opportunities to 2030
1.4 Key Biosimilars Market Trends and Challenges
1.4.1 Biosimilars Market Drivers and Trends
1.4.2 Biosimilars Market Challenges
1.5 Competitive Landscape and Key Players
1.6 Competitive Analysis- Growth Strategies Adopted by Leading Biosimilars Companies
2. BIOSIMILARS MARKET SIZE OUTLOOK TO 2030
2.1 Biosimilars Market Size Outlook, USD Million, 2021- 2030
2.2 Biosimilars Incremental Market Growth Outlook, %, 2021- 2030
2.3 Segment Snapshot, 2024
3. BIOSIMILARS MARKET- STRATEGIC ANALYSIS REVIEW
3.1 Porter's Five Forces Analysis
* Threat of New Entrants
* Threat of Substitutes
* Intensity of Competitive Rivalry
* Bargaining Power of Buyers
* Bargaining Power of Suppliers
3.2 Value Chain Analysis
3.3 SWOT Analysis
4. BIOSIMILARS MARKET SEGMENTATION ANALYSIS AND OUTLOOK
4.1 Market Segmentation and Scope
4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
By Product
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
By Application
Oncology
Blood Disorders
Growth Hormonal Deficiency
Rheumatoid Arthritis
Chronic & Autoimmune Disorders
Others
4.3 Growth Prospects and Niche Opportunities, 2023- 2030
4.4 Regional comparison of Market Growth, CAGR, 2023-2030
5. REGION-WISE MARKET OUTLOOK TO 2030
5.1 Key Findings for Asia Pacific Biosimilars Market, 2025
5.2 Asia Pacific Biosimilars Market Size Outlook by Type, 2021- 2030
5.3 Asia Pacific Biosimilars Market Size Outlook by Application, 2021- 2030
5.4 Key Findings for Europe Biosimilars Market, 2025
5.5 Europe Biosimilars Market Size Outlook by Type, 2021- 2030
5.6 Europe Biosimilars Market Size Outlook by Application, 2021- 2030
5.7 Key Findings for North America Biosimilars Market, 2025
5.8 North America Biosimilars Market Size Outlook by Type, 2021- 2030
5.9 North America Biosimilars Market Size Outlook by Application, 2021- 2030
5.10 Key Findings for South America Biosimilars Market, 2025
5.11 South America Pacific Biosimilars Market Size Outlook by Type, 2021- 2030
5.12 South America Biosimilars Market Size Outlook by Application, 2021- 2030
5.13 Key Findings for Middle East and Africa Biosimilars Market, 2025
5.14 Middle East Africa Biosimilars Market Size Outlook by Type, 2021- 2030
5.15 Middle East Africa Biosimilars Market Size Outlook by Application, 2021- 2030
6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030
6.1 US Biosimilars Market Size Outlook and Revenue Growth Forecasts
6.2 US Biosimilars Industry Drivers and Opportunities
6.3 Canada Market Size Outlook and Revenue Growth Forecasts
6.4 Canada Biosimilars Industry Drivers and Opportunities
6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
6.6 Mexico Biosimilars Industry Drivers and Opportunities
6.7 Germany Market Size Outlook and Revenue Growth Forecasts
6.8 Germany Biosimilars Industry Drivers and Opportunities
6.9 France Market Size Outlook and Revenue Growth Forecasts
6.10 France Biosimilars Industry Drivers and Opportunities
6.11 UK Market Size Outlook and Revenue Growth Forecasts
6.12 UK Biosimilars Industry Drivers and Opportunities
6.13 Spain Market Size Outlook and Revenue Growth Forecasts
6.14 Spain Biosimilars Industry Drivers and Opportunities
6.16 Italy Market Size Outlook and Revenue Growth Forecasts
6.16 Italy Biosimilars Industry Drivers and Opportunities
6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
6.18 Rest of Europe Biosimilars Industry Drivers and Opportunities
6.19 China Market Size Outlook and Revenue Growth Forecasts
6.20 China Biosimilars Industry Drivers and Opportunities
6.21 India Market Size Outlook and Revenue Growth Forecasts
6.22 India Biosimilars Industry Drivers and Opportunities
6.23 Japan Market Size Outlook and Revenue Growth Forecasts
6.24 Japan Biosimilars Industry Drivers and Opportunities
6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
6.26 South Korea Biosimilars Industry Drivers and Opportunities
6.27 Australia Market Size Outlook and Revenue Growth Forecasts
6.28 Australia Biosimilars Industry Drivers and Opportunities
6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
6.30 South East Asia Biosimilars Industry Drivers and Opportunities
6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
6.32 Rest of Asia Pacific Biosimilars Industry Drivers and Opportunities
6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
6.34 Brazil Biosimilars Industry Drivers and Opportunities
6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
6.36 Argentina Biosimilars Industry Drivers and Opportunities
6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
6.38 Rest of South America Biosimilars Industry Drivers and Opportunities
6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
6.40 Middle East Biosimilars Industry Drivers and Opportunities
6.41 Africa Market Size Outlook and Revenue Growth Forecasts
6.42 Africa Biosimilars Industry Drivers and Opportunities
7. BIOSIMILARS MARKET OUTLOOK ACROSS SCENARIOS
7.1 Low Growth Case
7.2 Reference Growth Case
7.3 High Growth Case
8. BIOSIMILARS COMPANY PROFILES
8.1 Profiles of Leading Biosimilars Companies in the Market
8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
8.3 Financial Performance and Key Metrics
Amega Biotech S.A.S.
Amgen Inc
Amneal Pharmaceuticals Inc
Apotex Inc
BIOCAD
Biocon Ltd
Boehringer Ingelheim International GmbH
Celltrion Healthcare Co. Ltd
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius SE & Co. KGaA
Fujifilm Kyowa Kirin Biologics Co. Ltd
Intas Pharmaceuticals Ltd
Kashiv Biosciences LLC
mAbxience S.L.
Novartis AG
Pfizer Inc
Probiomed S.A. de C.V.
Reliance Life Sciences Pvt. Ltd
Samsung Bioepis Co. Ltd
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd
USV Private Ltd.
9. APPENDIX
9.1 Scope of the Report
9.2 Research Methodology and Data Sources
9.3 Glossary of Terms
9.4 Market Definitions
9.5 Contact Information
